NCT06297668 - A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 29, 2024

Primary Completion Date

June 11, 2024

Study Completion Date

June 11, 2024

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Treatment A: BGF MDI HFA

Participants will receive 4 inhalations of BGF MDI HFA as a single dose with AeroChamber Plus Flow-Vu spacer.

DRUG

Treatment B: BGF MDI HFO

Participants will receive 4 inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer.

DRUG

Treatment C: BGF MDI HFO

Participants will receive 4 inhalations of BGF MDI HFO as a single dose without spacer.

DEVICE

AeroChamber Plus Flow-Vu spacer

Participants will receive 4 inhalations of BGF MDI HFA (Treatment A) and BGF MDI HFO (Treatment B) as a single dose with spacer.

Trial Locations (1)

Research Site, Berlin